The efficacy and safety of lowdose oral allergovaccine in atopic bronchial asthma
Vykhrystsenka L.R., Novikov D.K.
Background: Development of mucosal methods of allergen specific immunotherapy (SIT) needs the highlighting research in allergy.
Aim: The main purpose of research was to study the efficacy and safety of lowdose oral allergovaccine AV1P (producer “Dialek”, Minsk) the composition of which were obtained include home dust mite allergens for the treatment of patients with atopic bronchial asthma.
Methods: A randomized, open pragmatic in the parallel group study was performed. The 33 patients with atopic bronchial asthma received lowdose oral allergovaccine AV1P, in the second group included 22 patients who received standard drug treatment of atopic bronchial asthma. The study had a 6 months of randomized treatment. The primary end points were clinical signs and medication of asthma, and secondary variables were skin hypersensitivity, serum level of specific IgE and level of IL10, TGF.
Results: Receiving oral allergovaccine helped reduce (p=0,03) of asthma symptoms (AST), reducing the need for 2agonists to 30,5% (p<0,001), reducing the number of asthma exacerbations, improve the quality of life of patients with asthma (AQ20). Excellent results were observed in 16% of cases, good in 71%, satisfactory in 13%. The treatment, including admission allergovaccine was more effective than pharmacotherapy in atopic bronchial asthma (p<0,05). The study proved the high safety of lowdose oral allergovaccine. Conclusion: The lowdose oral allergovaccine AV2P reduced the symptoms of asthma, prevented exacerbation of asthma and had high safety. The treatment by allergovaccine AV2P decreased dermal sensibilization to an allergen, level of specific IgE and level of IL10, TGF.